Chinese pharma names flock to ECM market

By Jonathan Breen
23 Jan 2020

There was a burst of activity from Chinese pharmaceutical and biotechnology companies in the equity capital markets this week, as the sector took centre stage following the spread of a flu-like virus that has already claimed lives on the mainland. Jonathan Breen reports.

A confluence of events has hit the pharmaceuticals sector in January. The novel strain of coronavirus, thought to have originated in Wuhan, in central China’s Hubei province, has infected hundreds on the mainland and so far caused at least 17 deaths in the country.

The shock of the ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial